If you are a person living with hATTR amyloidosis, or a caregiver for a person living with hATTR amyloidosis, we would greatly appreciate it if you could take 15 minutes to complete a questionnaire regarding Tegsedi, a medication recently approved by Health Canada. You don’t need to have experience with Tegsedi to participate. The survey closes March 1, 2019 and your input is vital to ensuring that Canadian patients have access to this therapy.
To learn more, please click here.